NEJM at ESMO - Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

N Engl J Med. 2025 Feb 13;392(7):e21. doi: 10.1056/NEJMe2411486. Epub 2024 Sep 16.
No abstract available

Publication types

  • Editorial